Incivek Approved for Hepatitis C

INCIVEK (telaprevir) 375mg tablets by Vertex Pharmaceuticals
INCIVEK (telaprevir) 375mg tablets by Vertex Pharmaceuticals

Vertex Pharmaceuticals announced that the FDA has approved Incivek (telaprevir) tablets for the treatment of patients with genotype 1 chronic hepatitis C with compensated liver disease. Incivek is indicated for use in treatment-naïve patients and for previously treated patients who did not achieve a viral cure (relapsers, partial responders and null responders). The approval of Incivek was based on data from three Phase 3 studies, which showed that patients who received Incivek, in combination with pegylated-interferon and ribavirin, achieved significantly higher rates of sustained viral response compared with those who received pegylated-interferon and ribavirin alone, regardless of their prior treatment experience. Sustained viral response was observed in 79% of treatment-naïve patients, 86% of relapsers, 59% of partial responders, and 32% of null responders compared with 46%, 22% 15%, and 5%, respectively, of patients who received pegylated-interferon and ribavirin alone.

Incivek will be available this week in a 375mg dosage strength tablet.

For more information call (855) 837-8394 or visit www.incivek.com